Brentuximab vedotin for relapse or progression therapy after allogeneic hematopoietic stem cell transplantation in relapsed / refractory classic Hodgkin lymphoma

被引：0
|
作者：
Mikhailova, N. [1 ]
Popova, M. [1 ]
Kondakova, E. [1 ]
Ivanova, M. [1 ]
Borzenkova, E. [1 ]
Alaynskiy, A. [1 ]
Bondarenko, S. [1 ]
Afanasyev, B. [1 ]
Babenko, E. [1 ]
机构：
[1] First St Petersburg Pavlov State Med Univ, St Petersburg, Russia
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P728
引用
收藏
页码：S503 / S503
页数：1
相关论文
共 50 条
  • [41] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
    Ferhanoglu, B.
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Paydas, S.
    HAEMATOLOGICA, 2014, 99 : 675 - 676
  • [42] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
    Mei, Matthew
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Armenian, Saro
    Chen, Robert
    Rosen, Steven
    Forman, Stephen
    Popplewell, Leslie
    Kwak, Larry
    Martin, Peter
    Maddocks, Kami
    Bond, David
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
  • [43] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Damlaj, Moussab
    Abuelgasim, Khadega A.
    Alhejazi, Ayman
    Alahmari, Bader
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2020, 55 (12) : 2322 - 2325
  • [44] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Moussab Damlaj
    Khadega A. Abuelgasim
    Ayman Alhejazi
    Bader Alahmari
    Ahmed Alaskar
    Mohsen Alzahrani
    Bone Marrow Transplantation, 2020, 55 : 2322 - 2325
  • [45] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [46] Functional Imaging Predicts Progression-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Relapsed/Refractory Hodgkin Lymphoma
    Cho, Christina
    Eaton, Anne
    Barker, Juliet N.
    Castro-Malaspina, Hugo
    Devlin, Sean M.
    Moskowitz, Alison
    Sauter, Craig S.
    Moskowitz, Craig H.
    Perales, Miguel-Angel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S218 - S219
  • [47] Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma
    Fernandez, Karen S.
    Mavers, Melissa
    Marks, Lianna J.
    Agarwal, Rajni
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (02) : E191 - E194
  • [48] Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma
    Colunga-Pedraza, Panelperla R. R.
    Ulises Coronado-Alejandro, Edgar
    De La Garza, Fernando
    Gomez Gomez, Eliezer Tomas
    Gomez-De Leon, Andres
    Colunga Pedraza, Julia Esther
    Homero Gutierrez-Aguirre, Cesar
    Cantu Rodriguez, Olga Graciela
    Gomez-Almaguer, David
    BLOOD, 2021, 138
  • [49] Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Johnston, Karissa
    Szabo, Shelagh
    Connors, Joseph M.
    Yasenchak, Christopher A.
    BLOOD, 2017, 130
  • [50] Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Thomas, Sandra H.
    Siddiqi, Tanya
    Popplewell, Leslie
    Faro, Len
    Nademanee, Auayporn
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (11) : 1864 - 1868
12345